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The calcium pump plasma 
membrane Ca2+-ATPase 2 (PMCA2) 
regulates breast cancer cell 
proliferation and sensitivity to 
doxorubicin
Amelia A. Peters1, Michael J. G. Milevskiy2, Wei C. Lee1, Merril C. Curry1, Chanel E. Smart3,4, 
Jodi M. Saunus3,5, Lynne Reid3,5, Leonard da Silva3,5, Daneth L. Marcial1, Eloise Dray6, 
Melissa A. Brown2, Sunil R. Lakhani3,4,7, Sarah J. Roberts-Thomson1 & Gregory R. Monteith1,8,†
Regulation of Ca2+ transport is vital in physiological processes, including lactation, proliferation and 
apoptosis. The plasmalemmal Ca2+ pump isoform 2 (PMCA2) a calcium ion efflux pump, was the first 
protein identified to be crucial in the transport of Ca2+ ions into milk during lactation in mice. In these 
studies we show that PMCA2 is also expressed in human epithelia undergoing lactational remodeling 
and also report strong PMCA2 staining on apical membranes of luminal epithelia in approximately 9% 
of human breast cancers we assessed. Membrane protein expression was not significantly associated 
with grade or hormone receptor status. However, PMCA2 mRNA levels were enriched in Basal breast 
cancers where it was positively correlated with survival. Silencing of PMCA2 reduced MDA-MB-231 
breast cancer cell proliferation, whereas silencing of the related isoforms PMCA1 and PMCA4 had no 
effect. PMCA2 silencing also sensitized MDA-MB-231 cells to the cytotoxic agent doxorubicin. Targeting 
PMCA2 alone or in combination with cytotoxic therapy may be worthy of investigation as a therapeutic 
strategy in breast cancer. PMCA2 mRNA levels are also a potential tool in identifying poor responders to 
therapy in women with Basal breast cancer.
The enrichment of milk with calcium is vital to neonatal and infant development. The process by which cal-
cium ions are transferred from the maternal blood supply into milk is highly coordinated, and involves specific 
calcium-permeable ion channels, and calcium pumps of both the secretory pathway and plasma membrane1–6. 
Recent studies have associated many of these specific calcium channels and pumps in processes important in 
breast cancer progression. Calcium signaling is a key regulator of many processes important in tumor progression 
including cellular proliferation, sensitivity to death stimuli, migration and invasion7. Indeed, specific calcium 
channels and pumps are identified as potential therapeutic targets in a number of cancer types including those of 
the prostate and breast8,9.
Expression of the canonical store-operated Ca2+ channel Orai110 is increased during lactation in mice1. 
In vitro models11,12 and more recently Orai1-null mice studies3, suggest that Orai1 plays an important role in 
the basolateral influx of Ca2+ across mammary epithelial cells during lactation. Orai1 is also a potential drug 
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target for some breast cancers on the basis of overexpression in some breast cancer cell lines1 and the ability of 
Orai1 silencing to reduce proliferation1,13, migration and invasion14 of breast cancer cells. Similarly, the secretory 
pathway Ca2+-ATPase isoform 2 (SPCA2) is associated with increased expression during lactation and specific 
breast cancer subtypes2,13. Silencing of SPCA2 reduces the proliferation of MCF-7 breast cancer cells in vitro and 
in vivo13.
The first specific protein identified as crucial in the process of Ca2+ ion transport during lactation was the 
plasmalemmal Ca2+ pump isoform 2 (PMCA2). In contrast to its related isoforms PMCA1 and PMCA4, PMCA2 
has a restricted tissue distribution with high levels of expression in cerebellar Purkinje neurons and cochlear hair 
cells, and in mammary glands during lactation15,16. In the rat and mouse mammary gland from lactating animals, 
PMCA2 is the predominant isoform6,17.
The role of PMCA2 in lactation is evidenced by the phenotype of PMCA2 null mice, which in addition to 
harboring defects in hearing and balance18, produce milk with significantly lower levels of calcium ions4. 
Additionally, weaning-associated PMCA2 suppression is a critical regulator of mammary epithelial apoptosis 
during involution19. Despite the important role of PMCA2 in the rodent mammary gland, there have been no 
studies of PMCA2 in the context of changes associated with lactation in humans, and there have been only lim-
ited studies of PMCA2 in the context of human breast cancer. PMCA2 mRNA levels are elevated in some breast 
cancer cell lines20, and a tissue microarray (TMA) study suggested that high expression of PMCA2 protein pre-
dicts poor survival in patients under 50 years of age, and is associated with HER2-positive disease19. In terms of 
functional evidence, exogenous expression of PMCA2 in T47D breast cancer cells reduces their sensitivity to cell 
death mediated by the calcium ionophore ionomycin19, and disruption of PMCA2’s interaction with calcineurin 
can trigger apoptosis in a variety of breast cancer cell lines21. However, the biological role of PMCA2 in breast 
carcinogenesis is generally not well understood, and the breast cancer subtypes where it might be most important 
and its potential utility as a therapeutic target are also still unclear.
In this study, we assessed the expression of PMCA2 protein in normal human breast tissue with histologic evi-
dence of lactational change, and the association between plasmalemmal PMCA2 protein and mRNA levels were 
assessed against histopathologic indicators and molecular subtype markers in breast cancer. We also evaluated the 
consequences of PMCA2 silencing on the proliferation of MDA-MB-231 breast cancer cells and their sensitivity 
to doxorubicin, an anthracycline chemotherapy frequently used to treat breast cancer.
Results
PMCA2 expression in human breast tissue exhibiting lactational remodeling and malignant 
transformation. Elevated PMCA2 is a feature of mammary glands from lactating mice2,22, however, PMCA2 
expression has not been assessed in human breast tissue undergoing lactational change. Therefore, we used 
unique tissue specimens from a breast cancer patient in the third trimester of pregnancy to investigate PMCA2 
expression in histologically normal glandular tissue in the context of lactational remodeling (morphological 
changes and positive β -casein staining are shown in Fig. 1A,B). Positive PMCA2 staining was observed on the 
plasma membranes of the epithelial cells, but not the surrounding stromal cells (Fig. 1C,D). The magnified image 
(Fig. 1D, arrows and insert) shows elevated PMCA2 expression on the luminal membrane compared to the basal 
membrane, consistent with a role for PMCA2 in the direct transport of Ca2+ into milk.
The possible pathological role of PMCA2 was assessed in human breast cancer samples. TMAs comprising 
96 breast tumors in duplicate were assessed for PMCA2 expression by IHC. The tumors were mostly histological 
grade 3 invasive ductal carcinomas (Supplementary Table 1). Figure 1E–G show examples of the three types 
of staining observed: no staining, cytoplasmic staining or membranous staining. Since PMCA2 is a plasma 
membrane Ca2+-transporter23, tumors with cytoplasmic but not membrane staining were classified as nega-
tive in our analysis. In total, 9/96 (~9%) of invasive tumors analyzed were PMCA2 plasma membrane positive 
(PMCA-PM+ ). We investigated associations between PMCA2 plasmalemmal expression and key prognostic 
indicators (histological grade, estrogen receptor (ER), progesterone receptor (PR) and HER2 status). A significant 
correlation between PMCA2-PM+ staining and the common breast cancer pathological markers, tumor grade, 
ER, PR or HER2 status was not observed (Table 1; Fisher’s exact tests, P > 0.05). However, we found a relationship 
with HER2-positivity (Table 1), with 8/9 of the PMCA2-PM+ cases also HER2+ according to clinical diagnostic 
criteria (> 6 copies of the ERBB2 gene by SISH). PMCA2 membrane expression is not particularly frequent in 
breast cancer and so in a cohort of 96 tumors this association did not reach statistical significance (Fisher’s exact 
P = 0.077), nevertheless given that the same trend was observed by others in a separate cohort19 this relationship 
could illuminate aspects of the biology underlying PMCA2 function and/or behavior of HER2+ breast tumors.
PMCA2 mRNA is significantly enriched in the Basal breast cancer molecular subtype where is 
it associated with survival. PMCA2, PMCA1 and PMCA4 mRNA levels were compared in breast cancer 
molecular subtypes24 from RSEM data from the TCGA consortium (Fig. 2A–C). Consistent with the IHC data 
presented above, there were individual breast cancers with relative high levels of PMCA2 (ATP2B2) in all of the 
molecular subtypes (Fig. 2A), this was not seen for PMCA1 (ATP2B1) or PMCA4 (ATP2B4) (Fig. 2B,C). PMCA2 
levels were, however, significantly enriched in the Basal molecular phenotype compared to HER2, Luminal A and 
Luminal B. Assessment of PMCA2 levels in Basal breast cancer cell lines identified PMCA2 as the minor isoform 
at the mRNA level in all basal breast cancer cell lines, with a trend for cell lines with higher levels of PMCA2 to be 
identified as Basal B (Fig. 3A). Indeed, PMCA2 levels were significantly greater in Basal B breast cancer cell lines 
compared to Basal A, a trend which was also observed for PMCA1 but not PMCA4 (Fig. 3B). In contrast to basal 
breast cancer cell line differences, PMCA2 levels were not significantly different between the recently defined 
triple-negative breast cancer (TNBC) molecular subtypes, BLIS, BLIA, LAR and MES (Fig. 4A) and there was 
no significant distribution of tumor subtypes in the low and high PMCA2 expression groups (Fig. 4B). However, 
assessment of patient survival in TNBC, identified PMCA2 levels as positively associated with patient survival, 
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this stratification was more pronounced than the stratification by the defined molecular subtypes in TNBC; BLIA, 
BLIS and MES (Fig. 4C). The positive association between PMCA2 levels and survival in Basal breast cancers was 
also observed in three different patient cohorts and this positive association was not consistently seen for PMCA1 
or PMCA4 (Supplementary Tables 2–4). PMCA2 mRNA was significantly elevated in specific breast cancers in 
both HER2 and Basal molecular subtypes, although within each subtype there was clear variation (Supplementary 
Fig. 1), this variance within Basal breast cancers may be the cause of the association between PMCA2 and survival 
in this subtype. Correlation analysis demonstrated a positive and significant correlation between PMCA2 and 
the Basal marker EGFR across all breast cancers, however, within the Basal subtype this association was negative 
(Supplementary Fig. 1).
Figure 1. PMCA2 expression in human breast tissue with lactational change and in breast cancer tissues. 
(A–D) Human breast sections with lactational change; (A) hematoxylin and eosin staining; (B) β -casein 
staining showing accumulation of milk protein in the lumen; (C,D) PMCA2 staining showing PMCA2 
accumulation on apical membranes of epithelial cells with lactational change. (E–G) Examples of PMCA2 
staining in breast cancer tissues; (E) PMCA2-negative cancer, showing light diffuse brown background staining, 
(F) More intense PMCA2 staining in the cytoplasm with no plasma membrane localization, these were also 
defined as PMCA2-negative cancer in our analysis, (G) Clear PMCA2 staining on the plasma membrane, 
these were defined as PMCA2-positive cancers (PMCA2-PM+ ) given the localization of the PMCA2 plasma 
membrane Ca2+ pump on the plasma membrane of these breast cancer cells. Original magnification 3×  
(A–C), 20× (D), 5× main images and 20× for insert (E–G).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:25505 | DOI: 10.1038/srep25505
PMCA mRNA levels in MDA-MB-231 Basal-like breast cancer cells. Given the focus of past studies 
of PMCA2 on luminal-like breast cancer cells, PMCA2 was assessed in MDA-MB-231 cells that are a repre-
sentative Basal B breast cancer cell line. PMCA2 mRNA was detected in MDA-MB-231 (Basal-B/Claudin-low 
molecular subtype25) by real-time RT-PCR. Its expression was >3-fold lower than PMCA1 and PMCA4 isoforms 
(Fig. 5A), which contrasts with rodent models of lactation where PMCA2 is the predominant isoform6,17 and 
was consistent with our RNAseq cell line data of MDA-MB-231 and other Basal breast cancer cell lines. PMCA2 
mRNA expression was significantly higher in confluent compared to sub-confluent cells (Fig. 5B). PMCA2 pro-
tein analysis in this cell line, suggested low levels of PMCA2 protein or a lack of full length PMCA2 protein in 
MDA-MB-231 cells, despite confidence in the antibody and techniques used (e.g. PMCA2 was readily detectable 
in human tissue; Fig. 1D,G). This may relate to the transient expression of full length PMCA2 protein during 
specific cell cycle stages and/or the potential for a PMCA2 fragment to be expressed which has been reported to 
have biological activity.
Silencing PMCA2 inhibits proliferation of breast cancer cells. Exogenous expression of PMCA2 
in luminal T47D breast cancer cells protects against ionomycin-mediated death19. Here, we assessed the effect 
of silencing endogenous PMCA2 on the proliferation of basal-like MDA-MB-231 cells, which express elevated 
PMCA2 mRNA compared to non-malignant breast cell lines26. PMCA isoform expression was silenced using 
Histopathologic 
indicators
PMCA2-PM 
positive n (%)
PMCA2 
negative n (%)
Fisher’s exact 
p value
Histological grade 1 and 2 3 2 (12) 7 (9) 15 (88) 68 (91) 0.67
ER Positive Negative 1 (5) 8 (11) 20 (95) 66 (89) 0.678
PR Positive Negative 0 (0) 9 (11) 13 (100) 73 (89) 0.353
HER2 Positive Negative 8 (14) 1 (3) 48 (86) 38 (97) 0.077
All tumors 9 (9) 87 (91)
Table 1.  Associations between PMCA2 expression and prognostic indicators in breast cancer. (ER, estrogen 
receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2).
Figure 2. PMCA2 is expressed most highly in Basal-like breast cancer. Log2 row-mean centred RSEM 
data sourced from the TCGA consortium. (A–C), expression for PMCA2, PMCA1 and PMCA4, respectively. 
Significance was found through a one-way ANOVA with a Tukey’s multiple comparisons test, ****P < 0.0001 
between the Basal-like tumors and HER2, LumA and LumB.
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siRNA, validating knockdown by real-time RT-PCR (Fig. 5C). PMCA2 silencing was not associated with a sig-
nificant compensatory change in PMCA1 or PMCA4 (Supplementary Fig. 2). Assessment of proliferating cells 
using EdU staining showed that PMCA2 silencing reduced the percentages of cells in S-phase by 17% and 33% 
(P < 0.05; Fig. 6A), with corresponding decreases in total cell number of 43% and 53%, using two separate siRNAs 
(Fig. 6B). In contrast, silencing PMCA1 or PMCA4 had no significant effect on cell cycle progression rate or cell 
number (Fig. 6).
Effects of PMCA2 silencing combined with cytotoxic chemotherapy on Ca2+ signaling and 
proliferation. The use of rational combination therapies reduce the likelihood that tumors will develop 
therapeutic resistance27, and that the patient will experience toxic side effects28. Others have shown PMCA2 defi-
ciency leads to increased sensitivity to Ca2+-induced apoptosis19, and we hypothesized that PMCA2 suppression 
may enhance the effects of cytotoxic chemotherapy on breast cancer cells. We tested this by assessing doxoru-
bicin efficacy in the siPMCA2 MDA-MB-231 model. Consistent with the anti-proliferative effects identified in 
high-content analysis (Fig. 6), PMCA2 silencing attenuated MDA-MB-231 cell proliferation (Fig. 7; *P < 0.05). 
A pulse treatment with a very low dose of doxorubicin (20 nM) had negligible impact on the proliferation of 
MDA-MB-231 cells transfected with control non-targeting siRNA (NT siRNA; Fig. 7, #P < 0.05). However, doxo-
rubicin promoted the anti-proliferative effects of PMCA2 silencing (Fig. 7, ^P < 0.05) and inhibited cell prolifer-
ation more effectively than PMCA2 silencing or doxorubicin treatment alone (Fig. 7). No morphological signs of 
promotion of cell death with PMCA2 silencing were observed (Supplementary movies).
Given the potential for PMCA2 to contribute to changes in or doxorubicin sensitivity via global or local effects 
on calcium signaling or even other pathways21 we assessed global Ca2+ signaling responses of PMCA2-silenced 
and non-silenced doxorubicin-treated MDA-MB-231 cells to three agents known to produce transient increases 
in intracellular free Ca2+ ([Ca2+]CYT): ATP, trypsin and thapsigargin (an inhibitor of the endoplasmic reticulum 
Ca2+ ATPase). We found that regardless of the stimulus used, increases in [Ca2+]CYT in doxorubicin-treated cells 
were not altered by PMCA2 silencing, in terms of both the nature of the recovery of [Ca2+]CYT (Fig. 8A) or the 
maximum [Ca2+]CYT level achieved (Fig. 8B). These data suggest that the effects of PMCA2 silencing on cell pro-
liferation is independent of effects on global levels of [Ca2+]CYT.
Figure 3. PMCA2 is dynamically expressed in Basal breast cancer cell lines. Expression values are derived 
from Variance Stabilized Data (VSD, a measure of expression coined by Klijn et al.53. (A) log2 VSD expression 
data in order of highest to lowest expressing cell line based on PMCA2/ATP2B2. Each column is colour-coded 
red for high and blue for low expression. (B) Average expression of Basal A vs Basal B cell lines. Significance was 
found using a two-tailed unpaired T test, *P < 0.05.
www.nature.com/scientificreports/
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Discussion
The altered expression of specific Ca2+ channels is a characterizing feature of many cancers7–9. These include 
enhanced expression of specific isoforms of transient receptor potential (TRP)29–31 and Orai Ca2+ permeable ion 
channels32,33, as well as voltage34–36 and ligand gated Ca2+ channels37–39. Although not as widely characterized, 
altered expression of particular isoforms of p-type Ca2+-ATPase family members is associated with specific can-
cer subtypes, for example, elevated levels of SPCA1 in basal-like breast cancers40 and of SERCA2 in colorectal 
cancers41,42. The identification of PMCA2 mRNA in breast cancer cell lines20,26, PMCA2 protein in clinical breast 
cancer specimens19, and a role for PMCA2 in the transport of Ca2+ into milk during lactation4, highlight the 
relevance of this p-type ATPase in the context of human breast cancer and the physiology of the human breast.
Our finding that PMCA2 is expressed at the apical membrane of luminal epithelia in the pre-lactational 
human breast is consistent with data from rodent models demonstrating that PMCA2 is a key pump respon-
sible for the efflux of Ca2+ from the maternal compartment into milk. In the breast cancer cohort assessed in 
this study, 9/96 tumors expressed PMCA2 in the tumor cell plasma membrane. Consistent with VanHouten 
et al.19, we found a positive association between PMCA2 expression and HER2 status, with eight out of the nine 
PMCA2 membrane-positive cases classified HER2+ . This relationship did not reach statistical significance, 
owing largely to the size of the PMCA2+ subgroup in our study (n = 9 cases). A key difference between our study 
and VanHouten’s was that we assessed the subcellular localization of PMCA2. We analyzed membrane-associated 
PMCA2 as a categorical variable, whereas the previous study used digital scoring to quantify overall tumor cell 
positivity as a continuous variable. This is an important distinction given that the membrane residence time of 
Figure 4. PMCA2 expression stratifies Basal breast cancers independent of TNBC subtypes. (A) Basal-like 
and Claudin-low breast cancers51 were assigned a TNBC subtype based on expression gene expression patterns 
from52; Basal-like Immune Activated (BLIA), Basal-like Immune Suppressed (BLIS), Luminal AR (LAR) 
and Mesenchymal (MES). (B) Distribution of TNBC-Subtypes in low and high expressing PMCA2 tumors 
and across all Basal-like and Claudin-low tumors. No significance was found between PMCA2 groupings 
via a χ 2 test, P-value = 0.825. (C) Relapse-free-survival (RFS) for each of the TNBC-Subtypes compared to 
PMCA2 expression groupings. No significance was found between BLIA and BLIS tumors (Log-rank P-value 
0.1488), however PMCA2 groupings were significant with a hazard ratio of 0.50 (95% CI 0.36 – 0.80) and 
P-value = 0.0024 comparing high expression to low.
www.nature.com/scientificreports/
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ion pumps is dynamic and often tightly regulated, and subcellular compartment-specific expression of PMCA2 
alternative splice isoforms43 has not been thoroughly investigated.
Our investigation of PMCA2 levels in molecular breast cancer subtypes supported our IHC data of high levels 
of PMCA2 across different breast cancer subtypes. Specific breast cancers of the Basal, Luminal A, Luminal B and 
HER2 molecular subtypes had high levels of PMCA2, this was not as obvious for PMCA1 and PMCA4. However, 
this large cohort identified that PMCA2 mRNA levels were significantly higher in basal breast cancers overall 
compared to Luminal A, Luminal B and HER2 subtypes. The absence of any differences in PMCA1 and PMCA4 
in the different molecular subtypes reinforces the potential unique roles of the PMCA2 isoform in the breast in 
both lactation and in breast cancer. Although PMCA2 levels were higher in Basal B vs Basal A breast cancer cell 
lines, PMCA2 levels were not different amongst the recently identified TNBC molecular subtypes BLIS, BLIA, 
LAR and MES. However, PMCA2 levels were highly correlated with patient survival in triple negative breast can-
cers and basal breast cancers, which was seen across multiple cohorts. In these cases, high levels of PMCA2 were 
associated with better patient survival. This is in contrast to a previous report of Oncomine cDNA microarray 
data in only patients under the age of 50, which found a negative association between high PMCA2 levels and 
survival19. Our identified relationship between high levels of PMCA2 mRNA and patient survival in basal breast 
cancers, may represent an ability for PMCA2 to identify less aggressive basal breast cancers and signify that 
PMCA2 overexpression is a not a driver in breast cancer. The potential dichotomy in PMCA2 levels between sub-
types and its correlation with survival in the basal subtype is exemplified by the very different association between 
EGFR and PMCA2 in all breast cancers (positive correlation) versus the basal subtype (negative correlation). 
Hence, within basal breast cancers, PMCA2 may associate with characteristics of better prognosis which may 
make it a biomarker for good survival. This association does not exclude the potential of PMCA2 as a drug target 
in some breast cancer cells, either via the previously proposed mechanism of promotion of apoptosis through 
PMCA2 inhibition19 and/or the anti-proliferative effects of PMCA2 inhibition identified in MDA-MB-231 cells 
Figure 5. PMCA mRNA levels in MDA-MB-231 breast cancer cells and silencing of PMCA isoforms in 
MDA-MB-231 cells. (A) PMCA isoform mRNA levels in confluent MDA-MB-231 cells relative to PMCA2 
mRNA. (B) PMCA2 mRNA levels in sub-confluent (sub-con.) and confluent (con.) MDA-MB-231 cells.  
(C) PMCA2, PMCA1 and PMCA4 siRNA mediated silencing, 120 h after transfection with non-targeting siRNA 
(siNT), PMCA2 siRNA (siPMCA2), PMCA1 siRNA (siPMCA1) or PMCA4 siRNA (siPMCA4). The data are 
mean ± SD (n = 3) and are from three independent experiments, *P < 0.05, unpaired t-test.
www.nature.com/scientificreports/
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in this study. These complex relationships and associations could be further explored by detailed comparisons of 
the consequences of PMCA2 silencing in different cell-lines as well as different patient derived xenograft models.
Previous studies of PMCA2 in human breast cancer cells have focused on the role of this Ca2+ pump in pro-
tection against cell death mediated by agents that produce sustained increases in [Ca2+]CYT19 or its role in apop-
tosis regulation through interactions with calcineurin21. However, calcium signaling also plays a vital role in cell 
cycle regulation in cancer cells7 and global inhibition of PMCA expression reduces the proliferation of ER+ , 
luminal-like MCF-7 breast cancer cells44. In these studies, PMCA2 was the only PMCA isoform associated with 
proliferation of basal-like MDA-MB-231 cells, despite the lower expression of this pump relative to other iso-
forms. The lack of any effect of PMCA1 silencing on cellular proliferation may seem surprising given that this 
isoform is the predominant regulator of global [Ca2+]CYT in MDA-MB-231 cells45. However, Curry et al. demon-
strated that despite only modest effects on global [Ca2+]CYT with PMCA4 silencing, PMCA4 but not PMCA1 
silencing augmented apoptosis mediated by the Bcl-2 inhibitor, ABT-263, likely through selective effects on Ca2+ 
dependent NFkB activity45. The ability of PMCA2 to regulate MDA-MB-231 proliferation may also be due to 
localized specific regulation of Ca2+ dependent transcription factors involved in proliferation. However, other 
Figure 6. Silencing PMCA2 in MDA-MB-231 breast cancer cells inhibits the percentage of cells in S-phase 
and reduces cell number. (A,B) Silencing PMCA2 for 120 h using ON-TARGETplus siRNA and siGenome 
siRNA inhibits (A) the percentage of EdU-positive cells and (B) cell number. Data are mean ± SD (n = 3) from 
3 independent experiments, *P < 0.05, one-way ANOVA, Tukey’s post hoc test (left panel) or unpaired t-test 
(right panel).
www.nature.com/scientificreports/
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mechanisms are also possible. For example, the pronounced increase of PMCA2 mRNA in MDA-MB-231 cells 
with increasing confluence in vitro may reflect dynamic expression of PMCA2 at critical stages of the cell cycle, 
such that silencing of PMCA2 has pronounced effects only at specific stages of cell division. Moreover, the ability 
of specific regions of PMCA2 to interact with calcineurin21 suggests that the entire intact PMCA2 protein may not 
be required to have a functional consequence in at least some breast cancer cells.
Our data raise the possibility that PMCA2 depletion or inhibition could be a chemo-sensitizing strategy in 
some breast cancer cells21. On the background of PMCA2 deficiency, we found that a low dose of doxorubicin was 
sufficient for pronounced inhibition of MDA-MB-231 proliferation in vitro, suggesting tumor-targeted PMCA2 
depletion or inhibition may allow the use of doxorubicin doses associated with a better side effect profile in these 
cells.
Conclusions
These data provide further evidence for an important role of PMCA2 in calcium transport during human lac-
tation, and the expression of PMCA2 in a significant percentage of breast cancers. PMCA2 function does not 
appear to be restricted to the regulation of cell death pathways in breast cancer cell lines, and may regulate other 
hallmarks of cancer including sustained cellular proliferation46. Targeting PMCA2 to reduce breast tumor cell 
proliferation and increase sensitivity to cytotoxic chemotherapy is a strategy worth further investigation.
Methods
Human clinical samples. Formalin-fixed, paraffin-embedded (FFPE) samples of histologically normal 
human breast tissue exhibiting pregnancy-induced lactational change were obtained from Pathology Queensland. 
This patient presented with breast cancer in the third trimester of pregnancy, and underwent a wide local excision 
procedure. Histopathologic diagnostic assessment revealed a grade 3 invasive ductal carcinoma of no special type 
Figure 7. PMCA2 silencing enhances the inhibitory effects of doxorubicin on MDA-MB-231 breast cancer 
cell proliferation. Cells were transfected with non-targeting siRNA (siNT) or PMCA2 siRNA (siPMCA2) for 
48 h, and then pulse treated with doxorubicin (Doxo, 20 nM) for 24 h. Cell area was assessed for 59 h. Data 
are mean ± SD (n = 4) from 4 independent experiments, statistical significance was assessed using two-way 
ANOVA with Tukey’s post hoc test for each time point, *P < 0.05, for siNT vs siPMCA2; #P < 0.05, siNT vs siNT 
Doxo; ¤P < 0.05, siNT Doxo vs siPMCA2 Doxo; ^P < 0.05, siPMCA2 vs siPMCA2 Doxo.
Figure 8. Effect of doxorubicin and PMCA2 silencing on Ca2+ signaling in MDA-MB-231 cells. Cells were 
transfected with non-targeting siRNA (siNT) or PMCA2 siRNA (siPMCA2) for 48 h, and pulse treated with 
doxorubicin (20 nM) for 24 h and then incubated for an additional 24 h. (A) Relative [Ca2+]CYT response to 
trypsin (100 nM), ATP (1 mM) or thapsigargin (2 μ M) in MDA-MB-231 cells treated with siNT or siPMCA2. 
Relative [Ca2+]CYT (solid line) ± SD (dotted line). (B) Mean peak relative [Ca2+]CYT (n = 3) ± SD from 3 
independent experiments.
www.nature.com/scientificreports/
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(negative for estrogen, progesterone and human epidermal growth factor receptors (‘triple-negative’)), associ-
ated with high-grade ductal carcinoma in situ and lymph node metastases. Immunohistochemistry (IHC) was 
performed on glandular tissue in the specimen that exhibited hyperplasia, but no evidence of in situ or invasive 
disease. Physiological hyperplasia is an expected feature in the pre-lactation breast.
For breast cancer studies, tissue microarray (TMA) sections containing duplicate tissue cores (0.6 mm) 
from 96 tumors (supplementary data, Table 1) were constructed using archival FFPE blocks from Pathology 
Queensland47. The retrospective analysis of archival human clinical samples in this study was approved the human 
research ethics committees at the Royal Brisbane and Women’s Hospital and The University of Queensland (UQ 
2005000785; RBHW 2005/022). All studies were conducted in accordance with institutional approved guidelines.
Immunohistochemistry. Tissue sections (4 μ m) were deparaffinized, rehydrated, washed and heated in 
0.01 M citrate buffer (pH 6) at 125 °C for 5 min and at 90 °C for 10 min in a decloaking chamber (Biocare Medical). 
Sections were stained using the rabbit anti-PMCA2 ATPase polyclonal antibody (1:300; PA1-915 Thermo-Fisher 
Scientific) or β -casein monoclonal antibody (1:100; sc-53189, Santa Cruz), and the MACH-1 Universal 
HRP-Polymer Detection Kit (Biocare Medical) according to the manufacturer’s instructions. Nuclei were coun-
terstained with hematoxylin using a Varistain Gemini ES Automated Slide Stainer (Thermo Fisher Scientific). 
The negative and positive controls were no primary antibody and cerebellar tissue, respectively. Stained tissue 
sections were scanned at 20× magnification using a ScanScope XT Digital Slide Scanner (Aperio), and evaluated 
by a blinded pathologist (LdS) using the following criteria: (1) positive: intense plasma membrane staining with 
or without cytoplasmic staining; (2) negative: cytoplasmic or no staining (since PMCA2 is a plasma membrane 
Ca2+-transporter).
Breast Tumor Expression Analysis. Analysis of RNA-Seq for PMCA2 (ATP2B2), PMCA1 (ATP2B1) and 
PMCA4 (ATP2B4) and breast cancer molecular markers (KRT5, ERBB2, MK167, FOXM1, AURKA, EGFR, PGR, 
ESR1, FOXA1 and TFF) utilized the publically available TCGA (The Cancer Genome Atlas) dataset accessi-
ble through cbioportal.org48. This dataset consisted of a total 1100 tumors, of these 845 were classified into the 
PAM50 intrinsic molecular subtypes (Basal-like (140), HER2-enriched (67), Luminal A (420), Luminal B (194) 
and Normal-like (24) (as postulated by Perou and Sorlie 24,49 by TCGA). The RNA-Seq data from the TCGA were 
processed by the RSEM software50 and was then log2 transformed and mean-centered by gene (row). Tumor sam-
ples were then hierarchically clustered based on their gene expression profiles using Multiple Experiment Viewer 
(MeV, PMID: 9843981, http://www.tm4.org/mev.html) via a Manhattan average-linkage based algorithm. Gene 
Pearson’s correlations and their corresponding P-values were determined in Microsoft Excel (Version 15.19.1) via 
the ‘correl’ function. Breast tumors from the University of North Carolina (UNC) cohort51 were assigned into one 
of the triple-negative breast cancer (TNBC) subtypes based on a published approach52. The UNC cohort contains 
a total of 230 Basal-like and Claudin-low tumors with 115 Basal-like Immune Suppressed (BLIS), 78 Basal-like 
Immune Activated (BLIA), 2 Luminal androgen receptor (LAR) and 26 Mesenchymal (MES).
Cell Line RNA-Seq. Cell line RNA-Seq was sourced from Klijn et al.53. These data have been mapped and 
normalized using their novel methodology of Variance Stabilized Data (VSD). Gene expression (Log2 normal-
ized VSD) values were extracted from this dataset for all available Basal-like breast cancer cell lines for PMCA2, 
PMCA1 and PMCA4 and displayed as shown without any further normalization.
Assignments of PMCA expression groups. Both the UNC51 and Veridex (VDX)54 cohorts utilize 
microarray expression. Affymetrix probe sets for VDX genes were combined and averaged and used in down-
stream analysis (PMCA2/ATP2B2 204685_s_at, 211586_s_at and 216120_s_at, PMCA1/ATP2B1 209281_s_at, 
212930_at and 215716_s_at and PMCA4/ATP2B4 205410_s_at, 212135_s_at and 212136_at). For high and low 
expression groups in the UNC and VDX cohorts of Basal-like and/or Claudin-low tumors, receiver-operator 
characteristic (ROC) curves were produced for PMCA2, PMCA1 and PMCA4 expression against survival out-
come (relapse-free survival (RFS) and distant-metastasis-free survival (DMFS)). These curves were produced 
using the software MedCalc (www.medcalc.org), with optimal values used to call expression cutoff points. 
Percentile cutoffs are reported in supplementary Tables.
Survival Analysis. Survival analysis was performed in both UNC and VDX cohorts and with the online tool 
Kaplan-Meier Plotter55. For the UNC and VDX cohorts, RFS and DMFS, respectively, were stratified on the basis 
of PMCA2, PMCA1 and PMCA4 expression groups as described above. Univariate Cox proportional-hazards 
regression was carried out using MedCalc with results reported in the supplementary data. The Kaplan-Meier 
curve was produced using Prism software with Log-rank hazards ratios and P-values reported with each figure. 
Survival analysis from the Kaplan-Meier Plotter cohort of breast tumors was done using the ‘Auto-select best cut-
off,’ feature on the website, which analyses the median, tertile and quartile cutoffs for the more significant P-value.
Cell culture. MDA-MB-231 cells (obtained from ATCC) were cultured in high-glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS and L-Glutamine (4 mmol/L) 
(Sigma-Aldrich) at 37 °C with 5% CO2. The cells were cultured for less than 10 passages before experimentation 
and were monitored for morphological changes. STR profiling is regularly performed to authenticate the cell line 
using the StemElite ID Profiling Kit (Promega) at QIMR Berghofer (the last relevant test for these studies was 
performed February 2014, Brisbane, Australia as experiments were finalized prior to this date). Cells were tested 
6-monthly for mycoplasma (MycoAlert Assay, Lonza).
Transfection with siRNA. MDA-MB-231 cells seeded in 96-well plates (5 × 103 cells/well) were transfected 
with Dharmacon ON-TARGETplus SMARTpool siRNA or siGENOME SMARTpool siRNA (GE Healthcare) at a 
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final concentration of 100 nmol/L using 0.1 μ L/well DharmaFECT 4 according to the manufacturer’s instructions. 
The following human ON-TARGETplus siRNAs were transfected: non-targeting (siNT, D-001810-10-05), PMCA1 
(siPMCA1, L-006115-00-0005), PMCA2 (siPMCA2, L-006116-00-0005) and PMCA4 (siPMCA4 L-006118-
00-0005). We also used the following human siGENOME siRNAs: non-targeting (siNT, D-001206-14-05) 
and PMCA2 (siPMCA2, M-006116-00-0005). Knockdown of PMCA2, PMCA1 or PMCA4 was confirmed by 
real-time RT-PCR at 120 h post-transfection.
Real-time RT-PCR. RNA was isolated as previously described26 and reverse transcribed using the 
Omniscript RT kit (Qiagen). Real-time RT-PCR was performed using Taqman Fast Universal PCR Master Mix 
and gene expression assays: PMCA1 (Hs00155949_m1), PMCA2 (Hs00155975_m1), PMCA4 (Hs00608066_m1) 
with 18S rRNA as an input control (4319413E). Reactions were performed using StepOnePlus system (Applied 
Biosystems) with universal cycling conditions. Relative mRNA expression levels were determined using the com-
parative CT method56.
EdU incorporation assays: cell proliferation and cell cycle. Total MDA-MB-231 cell numbers and the 
proportion in S-phase of the cell cycle were assessed as previously described57. Briefly, 120 h after siRNA trans-
fection, cells were treated with EdU (10 mmol/L), fixed with 3.7% formaldehyde, and permeabilized with 0.5% 
Triton X-100. The Click-iT reaction cocktail (Alexa Fluor 555; Life Technologies) was incubated with the cells, 
followed by DAPI (4′ 6-diamidino-2-phenylindole; 400 nmol/L). The cells were imaged with the ImageXpress® 
Micro (Molecular Devices) automated epiflourescent microscope (10× objective). The DAPI and EdU stained 
cells were detected as described previously57, and analysis was performed using the multiwavelength cell scoring 
application module (MetaXpress).
Treatment with a cytotoxic to assess cell proliferation and intracellular-free Ca2+ 
[Ca2+]CYT. MDA-MB-231 cells were transfected with siRNAs for 48 h as described above. Cells were pulse 
treated with Doxorubicin (Doxo, 20 nM) for 24 h, cells were washed twice with Phosphate Buffered Saline 
(PBS), and the media was replaced with standard growth media. To assess cell proliferation, the total area of 
the cells was assessed for a period of 59 h using a kinetic imaging system, IncuCyte ZOOM (Essen Bioscience). 
Intracellular-free Ca2+ [Ca2+]CYT was assessed 48 h after doxorubicin treatment using the BD PBX Calcium Assay 
Kit (BD Biosciences58) as described previously57 with minor modifications. Briefly, cells were loaded with the 
Calcium Indicator, 5% PBX Signal Enhancer and probenecid (500 μ mol/L) in physical salt solution (PSS; with 
1.8 mmol/L CaCl2) for 1 h at 37 °C. The loading solution was replaced with PSS containing nominal Ca2+, 5% 
PBX Signal Enhancer and probenecid (500 μ mol/L). Fluorescence was assessed with an excitation intensity of 
470–495 nm and a 515–575 nm emission filter using a Fluorescence Imaging Plate Reader (FLIPR)TETRA 
(Molecular Devices). Fluorescence was normalized to the baseline fluorescence and expressed as ‘relative 
[Ca2+]CYT’.
Statistical Analysis. Statistical associations between PMCA2 and breast cancer prognostic indicators were 
evaluated using the Fisher’s exact test. Statistical significance for the remaining data was assessed as described 
in individual figure legends. All statistical analyses were performed using GraphPad Prism (version 6.04 for 
Windows and version 6.0f for Mac OS X, GraphPad Software, Inc.).
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